Blue Jay Capital Management’s Ironwood Pharmaceuticals IRWD Stock Holding History

Blue Jay Capital Management’s Portfolio IRWD Stock Details IRWD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$8.87M	Sell	561,180 -244,770	-30%	-$3.56M	6.05%	4
2017 Q1	$11.5M	Sell	805,950 -116,259	-13%	-$1.59M	5.66%	4
2016 Q4	$11.8M	Buy	922,209 +56,559	+7%	+$714K	7.13%	4
2016 Q3	$11.5M	Sell	865,650 -114,708	-12%	-$1.34M	6.29%	8
2016 Q2	$10.7M	Buy	+980,358	New	+$9.58M	7.05%	9

Other funds holding IRWD

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Blue Jay Capital Management's IRWD Position: Q2 2017 in Review

Blue Jay Capital Management reduced its Ironwood Pharmaceuticals (IRWD) stake by 30% in Q2 2017, selling an estimated $3.56M and leaving 561,180 shares worth $8.87M. The position accounts for 6.05% of the portfolio, ranked #4.

Blue Jay Capital Management first reported a position in IRWD in Q2 2016 and has held it in 5 quarters since. The position peaked at $11.8M in Q4 2016. 167 funds tracked by Wall St. Rank hold IRWD as of Q2 2017.

Blue Jay Capital Management held 561,180 shares of Ironwood Pharmaceuticals worth $8.87M as of Q2 2017.
Blue Jay Capital Management sold 244,770 Ironwood Pharmaceuticals shares in Q2 2017, an estimated $3.56M.
Ironwood Pharmaceuticals made up 6.05% of Blue Jay Capital Management's portfolio in Q2 2017, its #4 holding.
Blue Jay Capital Management first reported a position in Ironwood Pharmaceuticals in Q2 2016 and has held it in 5 quarters since.
Blue Jay Capital Management's Ironwood Pharmaceuticals position peaked at $11.8M in Q4 2016.
167 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2017.

Based on Blue Jay Capital Management's 13F filing for Q2 2017, filed 11 Aug 2017.